Gabapentinoids, which include gabapentin and pregabalin, now rank among the most prescribed medicines in the world. Gabapentinoid drug poisoning risk is a real and growing public health concern that too few people talk about openly. In the United States, gabapentin has become the seventh most prescribed drug. In the UK, prescriptions have climbed sharply over the past decade. Demand for non-opioid pain relief has driven much of that growth, along with wider use for anxiety and insomnia. Yet the risk these medicines carry, one that begins even before a first dose, does not always come up in the conversation between clinician and patient.

A major study published in PLOS Medicine in 2026 examined over 1.3 million UK patients. Its findings are striking and deserve a much wider audience.

What the Research Found About Gabapentinoid Drug Poisoning Risk

Researchers used a self-controlled case series design. Each patient served as their own comparison, which removes many of the confounding factors that cloud other study types. That makes the findings particularly solid.

Among the 16,827 individuals in the analysis, gabapentinoid drug poisoning risk had already more than doubled in the 90 days before treatment began (adjusted incidence rate ratio of 2.09). The study found that over 85% of participants received opioids, antidepressants, or other psychiatric medicines in the six months before a poisoning event. Many were already navigating worsening pain, anxiety, insomnia, or other conditions when doctors wrote those gabapentinoid prescriptions.

Once treatment started, the risk stayed elevated, though it fell gradually over time. In the first 28 days, poisoning risk ran 81% higher than during non-treatment periods. Even in the longer run, it never returned to baseline. It sat 11% above reference levels throughout the remainder of the treatment period.

Starting gabapentinoids does not signal a return to safety. The risk shifts rather than disappears.

Gabapentinoid Drug Poisoning Risk Rises Sharply When Combined With Other Medicines

The most urgent finding is what happens when patients take gabapentinoids alongside opioids or benzodiazepines. During the first 28 days of gabapentinoid treatment, concurrent opioid use pushed the risk to more than twice the reference level. Concurrent benzodiazepine use pushed it to nearly four times the reference level. Taking all three together? The risk exceeded three times the baseline.

These are not rare combinations. In the study, 89% of participants had received opioids at some point during the observation period. Another 54.7% had used benzodiazepines. This is everyday prescribing reality for a great many people.

Gabapentinoids amplify the sedative effects of other central nervous system depressants. They also carry some potential for misuse, particularly among people with a history of substance use disorders. When those properties meet the depressant effects of opioids or benzodiazepines, the outcome can turn serious very quickly.

Why the Gabapentin Overdose Danger Peaks in the First Month of Treatment

The research gives a clear warning about timing. Gabapentin overdose danger does not simply start on the day a person picks up a prescription. Risk builds in the weeks before treatment and peaks in that very first month.

In the study, 76.2% of participants had a diagnosed mental health condition before the poisoning event. Around 47.6% had a diagnosis related to illicit drug use. Many were already managing difficult and fragile health situations when they started gabapentinoids. Starting a new medicine added another variable to an already complex picture.

For anyone beginning this type of treatment, and for the people around them, those first weeks call for real vigilance.

Gabapentin and Pregabalin Carry the Same Level of Risk

Some people assume pregabalin carries a higher risk than gabapentin, partly because misuse rates are higher in certain settings. The research does not support that assumption. When researchers compared patients taking only gabapentin with those taking only pregabalin, they found no meaningful difference in poisoning rates (adjusted incidence rate ratio of 1.04). Both drugs carry a comparable level of risk. Neither is the safer option.

What This Means for Patients, Families, and Communities

The evidence points in one direction. Patients need closer monitoring throughout gabapentinoid treatment, not just at the start. Clinicians should avoid combining these medicines with opioids or benzodiazepines wherever possible.

For families and communities, the key is understanding that gabapentinoid drug poisoning risk follows a pattern. It is highest before a prescription starts, remains elevated in the first month, and climbs further when other sedating medicines enter the picture. That pattern is predictable. Predictable risk creates real opportunities to act before something goes wrong.

Awareness will not solve everything. But it is where every meaningful response has to start.

Source: dbrecoveryresources